CELYAD SA/ADR (NASDAQ:CYAD) has been assigned an average rating of “Buy” from the seven brokerages that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $41.40.
A number of research analysts recently commented on CYAD shares. Zacks Investment Research raised CELYAD SA/ADR from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $52.00 price target on shares of CELYAD SA/ADR in a report on Friday, May 17th. William Blair reissued a “buy” rating on shares of CELYAD SA/ADR in a report on Monday, May 13th. Finally, Piper Jaffray Companies reduced their price target on CELYAD SA/ADR from $51.00 to $41.00 and set an “overweight” rating for the company in a report on Monday, April 1st.
Institutional investors and hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN boosted its holdings in CELYAD SA/ADR by 22.3% in the first quarter. Wells Fargo & Company MN now owns 7,614 shares of the company’s stock valued at $155,000 after purchasing an additional 1,390 shares during the last quarter. Morgan Stanley boosted its holdings in CELYAD SA/ADR by 29.9% in the first quarter. Morgan Stanley now owns 9,985 shares of the company’s stock valued at $204,000 after purchasing an additional 2,298 shares during the last quarter. Millennium Management LLC lifted its holdings in CELYAD SA/ADR by 69.6% during the 4th quarter. Millennium Management LLC now owns 90,597 shares of the company’s stock worth $1,645,000 after buying an additional 37,171 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its holdings in CELYAD SA/ADR by 4.1% during the 4th quarter. Victory Capital Management Inc. now owns 646,351 shares of the company’s stock worth $11,738,000 after buying an additional 25,189 shares during the last quarter. 7.25% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ CYAD traded down $0.43 on Friday, hitting $19.69. The company had a trading volume of 1,800 shares, compared to its average volume of 2,459. CELYAD SA/ADR has a 12-month low of $15.36 and a 12-month high of $32.18. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.36 and a quick ratio of 5.36. The company has a market capitalization of $198.58 million, a price-to-earnings ratio of -5.07 and a beta of 1.81.
About CELYAD SA/ADR
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
See Also: What is Liquidity?
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.